HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

CEAs

If you want to keep on top of the latest CEAs, below are our quick monthly searches of journals.  Please note this isn't meant to be comprehensive....if you want that, or any other searches, please contact us!

February 2017

1.    Bierbaum M, Schoffski O, Schliemann B, Kosters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health economics review. 2017;7(1):8.
2.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2017;29(Suppl 1):47-53.
3.    Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology (Baltimore, Md). 2017.
4.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2017;143(2):361-8.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2017;150:53-8.
6.    Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):206-12.
7.    Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia : the official journal of the World Federation of Hemophilia. 2017.
8.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2017;150:121-2.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2017;95s:S17-s27.
10.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017;39(2):288-302.e4.
11.    Fontaine C, Daures JP, Landais P. On the censored cost-effectiveness analysis using copula information. BMC medical research methodology. 2017;17(1):27.
12.    Garrison LP, Jr., Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):213-6.
13.    Green AL, Gregory R. Cost-utility analysis alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2017.
14.    Hansen KS, Ndyomugyenyi R, Magnussen P, Lal S, Clarke SE. Cost-effectiveness analysis of malaria rapid diagnostic tests for appropriate treatment of malaria at the community level in Uganda. Health policy and planning. 2017.
15.    Hassmiller Lich K, Cornejo DA, Mayorga ME, Pignone M, Tangka FK, Richardson LC, et al. Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina. Preventing chronic disease. 2017;14:E18.
16.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2017;26(1):79-84.
17.    Heinzel A, Muller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-oncology. 2017.
18.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2017;17(1):99-107.
19.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2017;15(1):95-111.
20.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2017;43(2):252-62.
21.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2017;35(2):249-58.
22.    Larsen B, Marcus B, Pekmezi D, Hartman S, Gilmer T. A Web-Based Physical Activity Intervention for Spanish-Speaking Latinas: A Costs and Cost-Effectiveness Analysis. Journal of medical Internet research. 2017;19(2):e43.
23.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2017;32(2):159-67.
24.    Muhlbacher AC, Sadler A. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017;20(2):266-72.
25.    Oksman E, Linna M, Horhammer I, Lammintakanen J, Talja M. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care. BMC health services research. 2017;17(1):138.
26.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2017;124(3):474-84.
27.    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in beta-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation. 2017.
28.    Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. International journal of radiation oncology, biology, physics. 2017;97(2):339-46.
29.    Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PloS one. 2017;12(2):e0171327.
30.    Seagle BL, Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic oncology. 2017.
31.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2017;33(2):359-69.
32.    Simmons SF, Hollingsworth EK, Long EA, Liu X, Shotwell MS, Keeler E, et al. Training Nonnursing Staff to Assist with Nutritional Care Delivery in Nursing Homes: A Cost-Effectiveness Analysis. Journal of the American Geriatrics Society. 2017;65(2):313-22.
33.    Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. Journal of orthopaedic trauma. 2017;31(2):64-70.
34.    Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC infectious diseases. 2017;17(1):156.
35.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2017;24(2):168-76.
36.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-Effectiveness Analysis of Initial Treatment Strategies for Nonembolic Acute Limb Ischemia Using Real-Word Data. Annals of vascular surgery. 2017;39:276-83.
37.    van Kampen RJ, Ramaekers BL, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. European journal of cancer (Oxford, England : 1990). 2017.
38.    Vinten A, Sample J, Ibiyemi A, Abdul-Salam Y, Stutter M. A tool for cost-effectiveness analysis of field scale sediment-bound phosphorus mitigation measures and application to analysis of spatial and temporal targeting in the Lunan Water catchment, Scotland. The Science of the total environment. 2017.
39.    Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Seminars in musculoskeletal radiology. 2017;21(1):37-42.
40.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017;118(2):220-5.
41.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017;28(2):643-52.


 January 2017

1.    Correction: Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2017;12(1):e0170848.
2.    Albright CM, MacGregor C, Sutton D, Theva M, Hughes BL, Werner EF. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2017;129(1):111-9.
3.    Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, et al. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PloS one. 2017;12(1):e0170258.
4.    Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic medicine : a journal of the British Diabetic Association. 2017.
5.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate. Contraception. 2017;95(1):77-89.
6.    Clement RC, Lang PJ, Pettett BJ, Overman RA, Ostrum RF, Tennant JN. Cost and Cost-effectiveness Analysis of Treatment Options for Sanders II and III Calcaneus Fractures In Laborers. Journal of orthopaedic trauma. 2017.
7.    de Jong LA, Dvortsin E, Janssen KJ, Postma MJ. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical therapeutics. 2017.
8.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2017;54(1):17-23.
9.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2017;35(1):65-82.
10.    Fernandes L, Roos EM, Overgaard S, Villadsen A, Sogaard R. Supervised neuromuscular exercise prior to hip and knee replacement: 12-month clinical effect and cost-utility analysis alongside a randomised controlled trial. BMC musculoskeletal disorders. 2017;18(1):5.
11.    Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, et al. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human vaccines & immunotherapeutics. 2017:0.
12.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2017;11(1):85-93.
13.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2017;265(1):2-10.
14.    Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, et al. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and outcomes research : CEOR. 2017;9:39-47.
15.    Grover R, Rueda S, Gurunluoglu R. Letter to Editor: Is Single-Stage Prosthetic Reconstruction Cost effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2017.
16.    Hansen TB, Zwisler AD, Berg SK, Sibilitz KL, Thygesen LC, Kjellberg J, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. European journal of preventive cardiology. 2017:2047487317689908.
17.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
18.    Huang QC, Ye D, Jiang XY, Li QL, Yao KY, Wang JB, et al. [Cost-effectiveness analysis on colorectal cancer screening program]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2017;38(1):65-8.
19.    Idrisov B, Murphy SM, Morrill T, Saadoun M, Lunze K, Shepard D. Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis. Substance abuse treatment, prevention, and policy. 2017;12(1):4.
20.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):1-10.
21.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2017;33(1):11-21.
22.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
23.    Kimura T, Igarashi A, Ikeda S, Nakajima K, Kashimura S, Kunitomi A, et al. A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. Journal of cardiology. 2017;69(1):89-97.
24.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost Utility Analysis for the use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Post-Mastectomy Patients. Plastic and reconstructive surgery. 2017.
25.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2017;35(1):178-87.
26.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2017;37(1):94-103.
27.    Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017.
28.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2017;73(1):201-16.
29.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2017;37(1):85-94.
30.    Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. The New England journal of medicine. 2017;376(3):203-5.
31.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2017;20(1):8-18.
32.    Rivera F, Valladares M, Gea S, Lopez-Martinez N. Cost-effectiveness analysis in the Spanish setting of the peak trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Journal of medical economics. 2017:1-27.
33.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2017;127(1):29-37.
34.    Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. Journal of medical economics. 2017:1-11.
35.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017;18(1):e41-e7.
36.    Yang MC, Tan EC, Su JJ. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human vaccines & immunotherapeutics. 2017;13(1):81-9.
37.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2017;161(1):16-24.
38.    Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European journal of health economics : HEPAC : health economics in prevention and care. 2017.


December 2016

1.    Berm EJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PloS one. 2016;11(12):e0169065.
2.    Bohensky MA, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):1009-15.
3.    Castro Jaramillo HE, Moreno Viscaya M, Mejia AE. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. International journal of technology assessment in health care. 2016;32(5):337-47.
4.    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, et al. Directly acting antivirals combination for elderly patients with Chronic Hepatitis C: a Cost-Effectiveness Analysis. Liver international : official journal of the International Association for the Study of the Liver. 2016.
5.    Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis research. 2016;150:53-8.
6.    Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, et al. Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016.
7.    Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thrombosis research. 2016.
8.    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 2016.
9.    Garrison LP, Jr., Zimmermann MR, Young CH, Crittendon J, Genereux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular revascularization medicine : including molecular interventions. 2016.
10.    Glassman A, Canon O, Silverman R. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2016;19(8):913-20.
11.    Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in therapy. 2017;34(1):207-20.
12.    Isaranuwatchai W, Alam F, Hoch J, Boet S. A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of educational evaluation for health professions. 2017;13:44.
13.    Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert review of pharmacoeconomics & outcomes research. 2016:1-9.
14.    Jiang M, You JH. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovascular drugs and therapy. 2016.
15.    Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clinical drug investigation. 2016.
16.    McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016.
17.    Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ open. 2016;6(12):e014010.
18.    Mohr NM, Stoltze A, Ahmed A, Kiscaden E, Shane D. Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. Internal and emergency medicine. 2016.
19.    Pinsky MR, Valentin A, Rubenfeld G. Intensive Care Medicine in 2050: cost-effectiveness analysis. Intensive care medicine. 2016.
20.    Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
21.    Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, et al. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. PharmacoEconomics. 2016.
22.    Shiffman D, Arellano AR, Caulfield MP, Louie JZ, Bare LA, Devlin JJ, et al. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. BMC cardiovascular disorders. 2016;16(1):251.
23.    Tan J, Liu L, Xie J, Hu L, Yang Q, Wang H. Cost-effectiveness analysis of ultrasound-guided Seldinger peripherally inserted central catheters (PICC). SpringerPlus. 2016;5(1):2051.
24.    Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2016.


November 2016

1.    Bugiantella W, Rondelli F, Mariani L, Polistena A, Sanguinetti A, Avenia N, et al. Cost-effectiveness analysis of the temporary percutaneous ileostomy for faecal diversion after colorectal resection in elderly. Aging clinical and experimental research. 2016.
2.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
3.    Ceballos M, Orozco LE, Valderrama CO, Londono DI, Lugo LH. Cost-effectiveness analysis of the use of a prophylactic antibiotic for patients undergoing lower limb amputation due to diabetes or vascular illness in Colombia. Annals of vascular surgery. 2016.
4.    Cui S, Tobe RG, Mo X, Liu X, Xu L, Li S. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. BMC infectious diseases. 2016;16(1):677.
5.    Davidson C. Uncertainty in evidence synthesis limits clinical applicability of a clinical and cost-effectiveness analysis of induction of labour methods. Evidence-based medicine. 2016;21(6):226.
6.    Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ open. 2016;6(11):e010776.
7.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
8.    Gama E, Were V, Ouma P, Desai M, Niessen L, Buff AM, et al. Large-scale implementation of disease control programmes: a cost-effectiveness analysis of long-lasting insecticide-treated bed net distribution channels in a malaria-endemic area of western Kenya-a study protocol. BMJ open. 2016;6(11):e012776.
9.    Greenberg D, Neumann PJ. Cost-Effectiveness Analysis Expands its Reach Worldwide. Value in health regional issues. 2016;10:101-2.
10.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-11.
11.    Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2016.
12.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016;10(6):924-36.
13.    Kelly RJ, Smith TJ. Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1814-6.
14.    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric Surgery for Nonalcoholic Steatohepatitis: A Clinical and Cost-Effectiveness Analysis. Hepatology (Baltimore, Md). 2016.
15.    Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2016.
16.    Lee D, Park SM. Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies to Prevent Perinatal Transmission in North Korea: Selective Vaccination vs. Universal Vaccination. PloS one. 2016;11(11):e0165879.
17.    Lee HD, Jeon CH, Chung NS, Seo YW. Cost-Utility Analysis of Pedicle Screw Removal after Successful Posterior Instrumented Fusion in Thoracolumbar Burst Fractures. Spine. 2016.
18.    Luttjeboer J, Setiawan D, Cao Q, Cahh Daemen T, Postma MJ. Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. Vaccine. 2016;34(50):6381-7.
19.    Mantopoulos T, Mitchell PM, Welton NJ, McManus R, Andronis L. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(8):927-38.
20.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(11):1846-55.
21.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016;44(10):1090-101.
22.    Nogueira TE, Esfandiari S, Leles CR. Cost-effectiveness analysis of the single-implant mandibular overdenture versus conventional complete denture: study protocol for a randomized controlled trial. Trials. 2016;17(1):533.
23.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-9.
24.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(11):796-804.
25.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016;38(11):2430-46.e3.
26.    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current medical research and opinion. 2016:1-11.
27.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016;95(5):1137-47.
28.    Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, et al. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World journal of surgery. 2016.
29.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016;72(11):1319-25.
30.    Tonmukayakul U, Arrow P. Cost-effectiveness analysis of the atraumatic restorative treatment-based approach to managing early childhood caries. Community dentistry and oral epidemiology. 2016.
31.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
32.    Wen F, Zheng H, Wu Y, Wheeler J, Zeng X, Fu P, et al. Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Scientific reports. 2016;6:36060.
33.    Wilkinson A, Anderson S, Wheeler SB. Screening for and Treating Postpartum Depression and Psychosis: A Cost-Effectiveness Analysis. Maternal and child health journal. 2016.
34.    Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: A revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery. 2016.


October 2016

1.    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. PharmacoEconomics. 2016.
2.    Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. Journal of cancer research and clinical oncology. 2016.
3.    El Alaoui S, Lindefors N. Combining Time-Driven Activity-Based Costing with Clinical Outcome in Cost-Effectiveness Analysis to Measure Value in Treatment of Depression. PloS one. 2016;11(10):e0165389.
4.    Twiner MJ, Marinica AL, Kuper K, Goodman A, Mahn JJ, Burla MJ, et al. Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
5.    Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. Journal of medical economics. 2016:1-19.
6.    Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, et al. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan. Journal of gastrointestinal cancer. 2016.
7.    Smajerova M, Petrasova H, Little J, Ovesna P, Andrasina T, Valek V, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World journal of gastroenterology. 2016;22(38):8605-14.
8.    Stevanovic J, de Jong LA, Kappelhoff BS, Dvortsin EP, Voorhaar M, Postma MJ. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PloS one. 2016;11(10):e0163550.
9.    Cradock AL, Barrett JL, Kenney EL, Giles CM, Ward ZJ, Long MW, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Preventive medicine. 2016.
10.    Park SK, Park SH, Lee MY, Park JH, Jeong JH, Lee EK. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical therapeutics. 2016.
11.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016:1-10.
12.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016;142(10):981-7.
13.    Keller A, Gericke C, Whitty JA, Yaxley J, Kua B, Coughlin G, et al. A Cost-Utility Analysis of Prostate Cancer Screening in Australia. Applied health economics and health policy. 2016.
14.    Karnon J, Shafie AS, Orji N, Usman SK. What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost effectiveness and resource allocation : C/E. 2016;14:11.
15.    Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2016.
16.    Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016.
17.    Rocke DJ, Goldstein DP, de Almeida JR. A Cost-Utility Analysis of Recurrent Laryngeal Nerve Monitoring in the Setting of Total Thyroidectomy. JAMA otolaryngology-- head & neck surgery. 2016.
18.    Mason SE, Kinross JM, Hendricks J, Arulampalam TH. Postoperative hypothermia and surgical site infection following peritoneal insufflation with warm, humidified carbon dioxide during laparoscopic colorectal surgery: a cohort study with cost-effectiveness analysis. Surgical endoscopy. 2016.
19.    Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. Journal of medical economics. 2016:1-29.
20.    Odnoletkova I, Ramaekers D, Nobels F, Goderis G, Aertgeerts B, Annemans L. Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis. PloS one. 2016;11(10):e0163997.
21.    Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of magnetic resonance imaging : JMRI. 2016.
22.    Walusimbi S, Kwesiga B, Rodrigues R, Haile M, de Costa A, Bogg L, et al. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda. BMC health services research. 2016;16(1):563.
23.    Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine in patients with type 1 or type 2 diabetes in Denmark. Journal of medical economics. 2016:1-19.
24.    Kotirum S, Chongmelaxme B, Chaiyakunapruk N. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis. 2016.
25.    Tawiah T, Hansen KS, Baiden F, Bruce J, Tivura M, Delimini R, et al. Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PloS one. 2016;11(10):e0164055.
26.    Smith AF, Sutton A, Shinkins B. EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS: RESPONSE. International journal of technology assessment in health care. 2016:1-2.
27.    Korolija Marinic D, Varga S. Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia. Clinical therapeutics. 2016;38(10s):e15.
28.    Dottino JA, Hasselblad V, Secord AA, Myers ER, Chino J, Havrilesky LJ. Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis. Obstetrics and gynecology. 2016;128(4):747-53.
29.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016;57(10):1669-79.
30.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
31.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016;159(3):565-73.
32.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016;30(10):985-96.
33.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016;10(5):391-401.
34.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016;4(10):818-25.
35.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures: A Decision and Cost-Effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016;23(10):1161-9.
36.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016;23(15):1590-8.
37.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016;21(4):263-71.
38.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016;19(10):995-1002.
39.    Angulo JC, Sanchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, et al. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. Actas urologicas espanolas. 2016;40(8):513-22.
40.    Gibbons JP, Nugent E, O'Donohoe N, Maher B, Egan B, Feeley M, et al. Experience with botulinum toxin therapy for axillary hyperhidrosis and comparison to modelled data for endoscopic thoracic sympathectomy - A quality of life and cost effectiveness analysis. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2016;14(5):260-4.


September 2016

1.    Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System - ERRATUM. Infection control and hospital epidemiology. 2016;37(9):1133.
2.    Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatology international. 2016;36(9):1291-300.
3.    Arrieta O, Anaya P, Morales-Oyarvide V, Ramirez-Tirado LA, Polanco AC. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):855-63.
4.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):426-7.
5.    Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, et al. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. The European journal of health economics : HEPAC : health economics in prevention and care. 2016.
6.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1082.
7.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
8.    Chang HW, Shin SH, Suh SH, Kim BS, Rho MH. Cost-Effectiveness Analysis of Endovascular Coiling versus Neurosurgical Clipping for Intracranial Aneurysms in Republic of Korea. Neurointervention. 2016;11(2):86-91.
9.    Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. International journal of technology assessment in health care. 2016:1-8.
10.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016;21(9):1099-106.
11.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016;33(9):1600-11.
12.    Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. 2016;160(1):187-96.
13.    Donovan P, McLeod D, Little R, Gordon L. Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. European journal of endocrinology. 2016.
14.    Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK. Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations. PharmacoEconomics. 2016.
15.    Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultyaev D, Lister J, et al. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. The European journal of health economics : HEPAC : health economics in prevention and care. 2016;17(7):911-21.
16.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016;37(9):1012-21.
17.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016;79(3):418-25.
18.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Human vaccines & immunotherapeutics. 2016;12(9):2269-77.
19.    Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA cardiology. 2016;1(6):666-72.
20.    Georgalis L, de Sanjose S, Esnaola M, Bosch FX, Diaz M. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2016;25(5):430-9.
21.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016;7(3):511-25.
22.    Hahn-Pedersen J, Worm M, Green W, Andreasen JN, Taylor M. Cost utility analysis of the SQ((R)) HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clinical and translational allergy. 2016;6(1):35.
23.    Hojjat H, Svider PF, Davoodian P, Hong RS, Folbe AJ, Eloy JA, et al. To image or not to image? A cost-effectiveness analysis of MRI for patients with asymmetric sensorineural hearing loss. The Laryngoscope. 2016.
24.    Igarashi A, Tang W, Cure S, Guerra I, Marie L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-10.
25.    Igarashi A, Tang W, Guerra I, Marie L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Current medical research and opinion. 2016:1-11.
26.    Kang JR, Sin AT, Cheung EV. Treatment of Massive Irreparable Rotator Cuff Tears: A Cost-effectiveness Analysis. Orthopedics. 2016:1-12.
27.    Kempfle JS, BuSaba NY, Dobrowski JM, Westover MB, Bianchi MT. A cost-effectiveness analysis of nasal surgery to increase continuous positive airway pressure adherence in sleep apnea patients with nasal obstruction. The Laryngoscope. 2016.
28.    Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in Postmastectomy Patients. Plastic and reconstructive surgery. 2016;138(3):537-47.
29.    Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2016.
30.    Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines: A cost-effectiveness analysis in Nigeria, South Africa, Uganda and India. AIDS (London, England). 2016.
31.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016;30(5):352-8.
32.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. The Journal of infectious diseases. 2016;214(5):685-8.
33.    Launio CC, Asis CA, Manalili RG, Javier EF. Cost-effectiveness analysis of farmers' rice straw management practices considering CH4 and N2O emissions. Journal of environmental management. 2016;183:245-52.
34.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016;37(9):1079-86.
35.    Lindkvist M, Feldman I. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L. Health and quality of life outcomes. 2016;14(1):134.
36.    Machado de Assis TS, Azeredo-da-Silva AL, Werneck GL, Rabello A. Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(8):464-71.
37.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016;53(9):591-9.
38.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016;39(9):859-72.
39.    Neary KC, Mormino MA, Wang H. Suture Button Fixation Versus Syndesmotic Screws in Supination-External Rotation Type 4 Injuries: A Cost-Effectiveness Analysis. The American journal of sports medicine. 2016.
40.    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, et al. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. Clinical drug investigation. 2016.
41.    Nichols BE, Boucher CA, van der Valk M, Rijnders BJ, van de Vijver DA. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. The Lancet Infectious diseases. 2016.
42.    Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics. 2016.
43.    Park KW, Boyer MI, Gelberman RH, Calfee RP, Stepan JG, Osei DA. Simultaneous Bilateral Versus Staged Bilateral Carpal Tunnel Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016.
44.    Pearson-Stuttard J, Hooton W, Critchley J, Capewell S, Collins M, Mason H, et al. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study. Journal of public health (Oxford, England). 2016.
45.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016;31(9):1061-7.
46.    Picot MC, Jaussent A, Neveu D, Kahane P, Crespel A, Gelisse P, et al. Cost-effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5-year follow-up study. Epilepsia. 2016.
47.    Ramponi F, Ronco C, Mason G, Rettore E, Marcelli D, Martino F, et al. Cost-effectiveness analysis of online hemodiafiltration versus high-flux hemodialysis. ClinicoEconomics and outcomes research : CEOR. 2016;8:531-40.
48.    Roberts MS. The Next Chapter in Cost-effectiveness Analysis. Jama. 2016;316(10):1049-50.
49.    Ruiz-Sanchez D, Peinado, II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Pena-Diaz J. Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncology letters. 2016;12(3):1935-40.
50.    Serra-Arbeloa P, Rabines-Juarez AO, Alvarez-Ruiz MS, Guillen-Grima F. Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis. Surgical oncology. 2016;25(3):205-11.
51.    Shim E. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines. The American journal of tropical medicine and hygiene. 2016.
52.    Siribumrungwong B, Noorit P, Wilasrusmee C, Leelahavarong P, Thakkinstian A, Teerawattananon Y. Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand. Phlebology / Venous Forum of the Royal Society of Medicine. 2016;31(8):573-81.
53.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016;8(3):149-58.
54.    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert review of pharmacoeconomics & outcomes research. 2016.
55.    Tromme I, Legrand C, Devleesschauwer B, Leiter U, Suciu S, Eggermont A, et al. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European journal of cancer (Oxford, England : 1990). 2016;67:38-45.
56.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016;34(9):913-23.
57.    Visco AG, Zyczynski H, Brubaker L, Nygaard I, Xu X, Lukacz ES, et al. Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial. Female pelvic medicine & reconstructive surgery. 2016;22(5):311-6.
58.    Yang MC, Tan EC, Su JJ. Cost-Effectiveness Analysis of Quadrivalent versus Trivalent Influenza Vaccine in Taiwan: A Lifetime Multi-Cohort Model. Human vaccines & immunotherapeutics. 2016:0.


August 2016

1.    Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy & behavior : E&B. 2016;63:79-88.
2.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Which method is best for the induction of labour? A systematic review, network meta-analysis and cost-effectiveness analysis. Health technology assessment (Winchester, England). 2016;20(65):1-584.
3.    Lee VW, Tsai RB, Chow IH, Yan BP, Kaya MG, Park JW, et al. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC cardiovascular disorders. 2016;16(1):167.
4.    de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology (Oxford, England). 2016.
5.    Vaidya V, Gangan N, Comerota A, Lurie F. Cost-effectiveness analysis of initial treatment strategies for nonembolic acute limb ischemia using real word data. Annals of vascular surgery. 2016.
6.    Zhang H, Huo M, Chao J, Liu P. Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. PloS one. 2016;11(8):e0161936.
7.    Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. 2016.
8.    Bustillo-Lecompte CF, Mehrvar M. Treatment of an actual slaughterhouse wastewater by integration of biological and advanced oxidation processes: Modeling, optimization, and cost-effectiveness analysis. Journal of environmental management. 2016;182:651-66.
9.    Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A Cost-Effectiveness Analysis Of Pre-Exposure Prophylaxis For The Prevention Of HIV Among Los Angeles County Men Who Have Sex With Men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016.
10.    Acevedo JR, Fero KE, Wilson B, Sacco AG, Mell LK, Coffey CS, et al. Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016.
11.    Canestaro W, Vodicka E, Downing D, Trussell J. Implications of Employer Coverage of Contraception: Cost-Effectiveness Analysis of Contraception Coverage Under an Employer Mandate. Contraception. 2016.
12.    Goyert N, Eeson G, Kagedan DJ, Behman R, Lemke M, Hallet J, et al. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy: A Cost-effectiveness Analysis. Annals of surgery. 2016.
13.    Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thrombosis research. 2016;145:119-25.
14.    Shemilt I, Khan N, Park S, Thomas J. Use of cost-effectiveness analysis to compare the efficiency of study identification methods in systematic reviews. Systematic reviews. 2016;5(1):140.
15.    Miller HJ, Neupane R, Fayezizadeh M, Majumder A, Marks JM. POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surgical endoscopy. 2016.
16.    Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate. CNS drugs. 2016.
17.    Tolla MT, Norheim OF, Memirie ST, Abdisa SG, Ababulgu A, Jerene D, et al. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E. 2016;14:10.
18.    McFarland A. A cost utility analysis of the clinical algorithm for nasogastric tube placement confirmation in adult hospital patients. Journal of advanced nursing. 2016.
19.    Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS medicine. 2016;13(8):e1002067.
20.    Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert review of gastroenterology & hepatology. 2016:1-9.
21.    Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. European journal of clinical pharmacology. 2016.
22.    Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2016.
23.    Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PloS one. 2016;11(8):e0160444.
24.    Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. International wound journal. 2016.
25.    van Keep M, Gairy K, Seshagiri D, Thilakarathne P, Lee D. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC cancer. 2016;16:598.
26.    Khunti K, Gillies CL, Dallosso H, Brady EM, Gray LJ, Kilgallen G, et al. Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes research and clinical practice. 2016;118:12-20.
27.    Chen YE, Kao SS, Chung RH. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan. PloS one. 2016;11(8):e0160599.
28.    Sabater E, Lopez-Guillermo A, Rueda A, Salar A, Oyaguez I, Collar JM. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied health economics and health policy. 2016;14(4):465-77.
29.    Buti M, Dominguez-Hernandez R, Oyaguez I, Casado MA. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. Gastroenterologia y hepatologia. 2016;39(7):449-57.
30.    Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Medley N, Dias S, et al. Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016;123(9):1462-70.
31.    McIntosh E, Gray A, Daniels J, Gill S, Ives N, Jenkinson C, et al. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial. Movement disorders : official journal of the Movement Disorder Society. 2016;31(8):1173-82.
32.    Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KK. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & lymphoma. 2016;57(8):1865-75.
33.    Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV medicine. 2016;17(7):505-15.
34.    Bagcioglu M, Demir A, Sulhan H, Karadag MA, Uslu M, Tekdogan UY. Comparison of flexible ureteroscopy and micropercutaneous nephrolithotomy in terms of cost-effectiveness: analysis of 111 procedures. Urolithiasis. 2016;44(4):339-44.


July 2016

1.    Ament JD, Yang Z, Nunley P, Stone MB, Lee D, Kim KD. Cost Utility Analysis of the Cervical Artificial Disc vs Fusion for the Treatment of 2-Level Symptomatic Degenerative Disc Disease: 5-Year Follow-up. Neurosurgery. 2016;79(1):135-45.
2.    Babu MA. Commentary: Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
3.    Brenner MJ. What Cost-Utility Analysis Can Teach Us About Facial Deformity: Gambles, Trade-offs, and Willingness to Pay. JAMA facial plastic surgery. 2016;18(4):249-50.
4.    Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Digestive diseases and sciences. 2016;61(7):2108-17.
5.    Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. The oncologist. 2016.
6.    Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Advances in therapy. 2016.
7.    Elias I, Ortega-Joaquin N, de la Cueva P, Del Pozo LJ, Moreno-Ramirez D, Boada A, et al. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. Actas dermo-sifiliograficas. 2016;107(6):498-508.
8.    Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PloS one. 2016;11(7):e0159340.
9.    Gancarczyk SM, Jang ES, Swart EP, Makhni EC, Kadiyala RK. Percutaneous Trigger Finger Release: A Cost-effectiveness Analysis. The Journal of the American Academy of Orthopaedic Surgeons. 2016;24(7):475-82.
10.    Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2016.
11.    Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, et al. The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. The British journal of radiology. 2016;89(1063):20150910.
12.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016;34(35):4243-9.
13.    Hernandez L, Guo S, Kinter E, Fay M. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of medical economics. 2016;19(7):684-95.
14.    Hofer F, Achelrod D, Stargardt T. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany. Applied health economics and health policy. 2016.
15.    Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-alpha administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therapeutic advances in gastroenterology. 2016;9(4):473-82.
16.    Kidholm K, Rasmussen MK, Andreasen JJ, Hansen J, Nielsen G, Spindler H, et al. Cost-Utility Analysis of a Cardiac Telerehabilitation Program: The Teledialog Project. Telemedicine journal and e-health : the official journal of the American Telemedicine Association. 2016;22(7):553-63.
17.    Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International journal of radiation oncology, biology, physics. 2016;95(4):1175-83.
18.    Kuznik A, Habib AG, Munube D, Lamorde M. Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. BMC health services research. 2016;16(1):304.
19.    Leal JR, Heitman SJ, Conly JM, Henderson EA, Manns BJ. Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System. Infection control and hospital epidemiology. 2016:1-8.
20.    Lee JK, Jo YH, Kang CN. Cost-effectiveness Analysis of Existing Pedicle Screws Reusing Technique in Extension Revision Operation for Adjacent Segmental Stenosis After Lumbar Posterolateral Fusion. Spine. 2016;41(13):E785-90.
21.    Liu CC, Rudmik L. A Cost-effectiveness Analysis of Early vs Late Tracheostomy. JAMA otolaryngology-- head & neck surgery. 2016.
22.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016;44(7):1771-80.
23.    Matteucci F, Solinas L, Turri V, Donati C, D'Errico V, Moretti A, et al. IntegoTM Infusion System: cost effectiveness analysis focusing on dosimetry, sterility and management. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the So. 2016.
24.    Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, et al. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of medical economics. 2016:1-33.
25.    Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics. 2016;34(7):709-21.
26.    Raykar N, Nigam A, Chisholm D. An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance. Cost effectiveness and resource allocation : C/E. 2016;14:9.
27.    Richard P, Phillips M, Smith W, Davidson D, Kim E, Kane G. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas. International journal of radiation oncology, biology, physics. 2016;95(3):999-1008.
28.    Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. The Laryngoscope. 2016.
29.    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Molken M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic advances in respiratory disease. 2016.
30.    Shrime MG, Verguet S, Johansson KA, Desalegn D, Jamison DT, Kruk ME. Task-sharing or public finance for the expansion of surgical access in rural Ethiopia: an extended cost-effectiveness analysis. Health policy and planning. 2016;31(6):706-16.
31.    Varghese L, Mungall B, Zhang XH, Hoet B. Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong. Human vaccines & immunotherapeutics. 2016:1-6.
32.    Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016;36(7):567-78.
33.    Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. 2016.
34.    Verhoef TI, Trend V, Kelly B, Robinson N, Fox P, Morris S. Cost-effectiveness analysis of offering free leisure centre memberships to physically inactive members of the public receiving state benefits: a case study. BMC public health. 2016;16:616.
35.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016;142(1):144-9.
36.    Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2016.
37.    Xu X, Ma YY, Zou HD. Cost-Utility Analysis of Cataract Surgery in Advanced Glaucoma Patients. Journal of glaucoma. 2016;25(7):e657-62.
38.    Zhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2016.
39.    Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, et al. Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine. 2016;95(27):e3762.


June 2016

1.    Lanzeta I, Mar J, Arrospide A. Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial. Gaceta sanitaria / SESPAS. 2016.
2.    Sjostrom S, Kopp Kallner H, Simeonova E, Madestam A, Gemzell-Danielsson K. Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis. PloS one. 2016;11(6):e0158645.
3.    Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient preference and adherence. 2016;10:1025-35.
4.    Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. Journal of medical genetics. 2016.
5.    Cromwell I, Gaudet M, Peacock SJ, Aquino-Parsons C. Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. BMC health services research. 2016;16(1):206.
6.    Mercer SW, Fitzpatrick B, Guthrie B, Fenwick E, Grieve E, Lawson K, et al. The CARE Plus study - a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised controlled trial and cost-utility analysis. BMC medicine. 2016;14(1):88.
7.    Taylor C, Thompson K, Finfer S, Higgins A, Jan S, Li Q, et al. Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST. The Lancet Respiratory medicine. 2016.
8.    Heard C, Chaboyer W, Anderson V, Gillespie BM, Whitty JA. Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of tissue viability. 2016.
9.    Hankin-Wei A, Rein DB, Hernandez-Romieu A, Kennedy MJ, Bulkow L, Rosenberg E, et al. Cost-effectiveness analysis of catch-up hepatitis A vaccination among unvaccinated/partially-vaccinated children. Vaccine. 2016.
10.    Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug safety. 2016.
11.    Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016.
12.    Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of medical economics. 2016:1-8.
13.    Furlan JC, Craven BC, Fehlings MG. Surgical Management of the Elderly With Traumatic Cervical Spinal Cord Injury: A Cost-Utility Analysis. Neurosurgery. 2016.
14.    Uruena A, Vizzotti C, San Juan JA. Response to Orellano et al. regarding cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine. 2016;34(28):3222.
15.    Orellano PW, Salomon OD. Will dengue vaccination be cost-effective for Argentina? Reply to letter by Uruena et al. regarding "Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission". Vaccine. 2016;34(28):3221.
16.    Yun BJ, Myriam Hunink MG, Prabhakar AM, Heng M, Liu SW, Qudsi R, et al. Diagnostic Imaging Strategies for Occult Hip Fractures - A Decision and Cost-effectiveness Analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 2016.
17.    Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? The Journal of asthma : official journal of the Association for the Care of Asthma. 2016:0.
18.    Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-Effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical decision making : an international journal of the Society for Medical Decision Making. 2016.
19.    Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatology international. 2016.
20.    Berrigan P, Bardouille T, MacLellan M, Mohamed IS, Murthy M. Cost-utility analysis of magnetoencephalography used to inform intracranial electrode placement in patients with drug resistant epilepsy: a model based analysis. Journal of evaluation in clinical practice. 2016.
21.    Pedersen K, Sorbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG : an international journal of obstetrics and gynaecology. 2016.
22.    Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of medical economics. 2016:1-8.
23.    Tuffaha HW, Roberts S, Chaboyer W, Gordon LG, Scuffham PA. Cost-effectiveness Analysis of Nutritional Support for the Prevention of Pressure Ulcers in High-Risk Hospitalized Patients. Advances in skin & wound care. 2016;29(6):261-7.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Zhou J, Zhao R, Wen F, Zhang P, Wu Y, Tang R, et al. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori. 2016;2016(3):294-300.
26.    Merry M, Boulware DR. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(12):1564-8.
27.    Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis. International forum of allergy & rhinology. 2016;6(6):582-9.
28.    O'Day K, Levy WC, Johnson M, Jacobson AF. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA. Applied health economics and health policy. 2016;14(3):361-73.
29.    Ono Y, Osuga K, Takura T, Nakamura M, Shibamoto K, Yamamoto A, et al. Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations. Journal of vascular and interventional radiology : JVIR. 2016;27(6):831-7.
30.    Foteff C, Kennedy S, Milton AH, Deger M, Payk F, Sanderson G. Cost-Utility Analysis of Cochlear Implantation in Australian Adults. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2016;37(5):454-61.
31.    Morris S, Patel NV, Dobson J, Featherstone RL, Richards T, Luengo-Fernandez R, et al. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. International journal of stroke : official journal of the International Stroke Society. 2016;11(4):446-53.
32.    Perez-Ruiz F, Diaz-Torne C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Journal of medical economics. 2016;19(6):604-10.
33.    Escolar-Albaladejo G, Baron-Esquivias G, Zamorano JL, Betegon-Nicolas L, Canal-Fontcuberta C, de Salas-Cansado M, et al. [Cost-effectiveness analysis of apixaban versus acetylsalicylic acid in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain]. Atencion primaria / Sociedad Espanola de Medicina de Familia y Comunitaria. 2016;48(6):394-405.
34.    Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. The Journal of asthma : official journal of the Association for the Care of Asthma. 2016;53(5):538-45.
35.    Larsen MH, Wahl AK, Krogstad AL, Aas E. Cost-utility Analysis of Supported Self-management with Motiva-tional Interviewing for Patients with Psoriasis. Acta dermato-venereologica. 2016;96(5):664-8.
36.    Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, et al. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades infecciosas y microbiologia clinica. 2016;34(6):361-71.
37.    Hansson E, Ekman I, Swedberg K, Wolf A, Dudas K, Ehlers L, et al. Person-centred care for patients with chronic heart failure - a cost-utility analysis. European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2016;15(4):276-84.
38.    van den Akker-van Marle ME, Moojen WA, Arts MP, Vleggeert-Lankamp CL, Peul WC. Interspinous process devices versus standard conventional surgical decompression for lumbar spinal stenosis: cost-utility analysis. The spine journal : official journal of the North American Spine Society. 2016;16(6):702-10.


May 2016
1.    Stomberg C, Albaugh M, Shiffman S, Sood N. A cost-effectiveness analysis of over-the-counter statins. The American journal of managed care. 2016;22(5):e294-303.
2.    de Sonneville-Koedoot C, Stolk E, Rietveld T, Franken MC. Response to "Putting the cart before the horse: A cost effectiveness analysis of treatments for stuttering in young children requires evidence that the treatments analyzed were effective". Journal of communication disorders. 2016.
3.    Gulliford MC, Charlton J, Booth HP, Fildes A, Khan O, Reddy M, et al. Health Services and Delivery Research.  Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records. Southampton (UK): NIHR Journals Library
4.    Castelnuovo G, Pietrabissa G, Cattivelli R, Manzoni GM, Molinari E. Not Only Clinical Efficacy in Psychological Treatments: Clinical Psychology Must Promote Cost-Benefit, Cost-Effectiveness, and Cost-Utility Analysis. Frontiers in psychology. 2016;7:563.
5.    Phibbs CS, Love SR, Jacobson AK, Edson R, Su P, Uyeda L, et al. At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
6.    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS. The Journal of infectious diseases. 2016.
7.    Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, et al. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease. Cardiovascular intervention and therapeutics. 2016.
8.    Penaloza-Ramos MC, Jowett S, Barton P, Roalfe A, Fletcher K, Taylor CJ, et al. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study. European journal of preventive cardiology. 2016.
9.    Fukuda H, Moriwaki K. Cost-Effectiveness Analysis of Safety-Engineered Devices. Infection control and hospital epidemiology. 2016:1-10.
10.    Romanelli M, Gilligan AM, Waycaster CR, Dini V. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. ClinicoEconomics and outcomes research : CEOR. 2016;8:153-61.
11.    Canestaro WJ. Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). Journal of general internal medicine. 2016.
12.    Qureshi N, Weng S, Hex N. The role of cost-effectiveness analysis in the development of indicators to support incentive-based behaviour in primary care in England. Journal of health services research & policy. 2016.
13.    Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, et al. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. International journal of circumpolar health. 2016;75:31115.
14.    Nguyen TP, Wright EP, Nguyen TT, Schuiling-Veninga CC, Bijlsma MJ, Nguyen TB, et al. Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam. PloS one. 2016;11(5):e0155699.
15.    Lodhia P, Gui C, Chandrasekaran S, Suarez-Ahedo C, Dirschl DR, Domb BG. The Economic Impact of Acetabular Labral Tears: A Cost-effectiveness Analysis Comparing Hip Arthroscopic Surgery and Structured Rehabilitation Alone in Patients Without Osteoarthritis. The American journal of sports medicine. 2016.
16.    Fusco F, Turchetti G. Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care. BMJ open. 2016;6(5):e009964.
17.    Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano R. Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain. Human vaccines & immunotherapeutics. 2016:0.
18.    Jiang M, You JH. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics. 2016;17(7):701-13.
19.    Kjerstad E, Tuntland HK. Reablement in community-dwelling older adults: a cost-effectiveness analysis alongside a randomized controlled trial. Health economics review. 2015;6(1):15.
20.    Gasparini R, Landa P, Amicizia D, Icardi G, Ricciardi W, de Waure C, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: A cost-effectiveness analysis. Human vaccines & immunotherapeutics. 2016:1-14.
21.    Granados-Garcia V, Contreras AM, Garcia-Pena C, Salinas-Escudero G, Thein HH, Flores YN. Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors. PloS one. 2016;11(5):e0154625.
22.    Zheng HR, Wen F, Wu YF, Wheeler JR, Li Q. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective. European journal of cancer care. 2016.
23.    Elias I, Oyaguez I, Alvarez-Sala LA, Garcia-Bragado F, Navarro A, Gonzalez P, et al. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016;40(n03):187-208.
24.    Riesco-Martinez MC, Berry SR, Ko YJ, Mittmann N, Giotis A, Lien K, et al. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of oncology practice / American Society of Clinical Oncology. 2016;12(6):e710-23.
25.    Sohn M, Talbert J, Moga DC, Blumenschein K. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. Attention deficit and hyperactivity disorders. 2016.
26.    Vennera MD, Valero A, Uria E, Forne C, Picado C. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical drug investigation. 2016.
27.    Haacker M, Fraser-Hurt N, Gorgens M. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis. PLoS medicine. 2016;13(5):e1002012.
28.    Wallbillich JJ, Forde B, Havrilesky LJ, Cohn DE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic oncology. 2016.
29.    Russell LB, Sinha A. Strengthening Cost-Effectiveness Analysis for Public Health Policy. American journal of preventive medicine. 2016;50(5 Suppl 1):S6-s12.
30.    Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. Omics : a journal of integrative biology. 2016;20(5):274-82.
31.    Okumura LM, Riveros BS, Gomes-da-Silva MM, Veroneze I. A cost-effectiveness analysis of two different antimicrobial stewardship programs. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2016;20(3):255-61.
32.    Luyten J, Naci H, Knapp M. Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-based mental health. 2016;19(2):49-53.
33.    Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy. 2016;36(5):472-81.
34.    Nwachukwu BU, Schairer WW, McCormick F, Dines DM, Craig EV, Gulotta LV. Arthroplasty for the surgical management of complex proximal humerus fractures in the elderly: a cost-utility analysis. Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons  [et al]. 2016;25(5):704-13.
35.    Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clinical drug investigation. 2016;36(5):377-87.
36.    Kapoor A, Shaffer N, Hanchate A, Roberts M, Smith K. Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis. Medical care. 2016;54(5):474-82.
37.    Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-Effectiveness Analysis of Deep Brain Stimulation in Patients with Parkinson's Disease in Japan. World neurosurgery. 2016;89:628-35.e1.
38.    Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. Journal of medical economics. 2016;19(5):445-61.
39.    Jain KM, Zulliger R, Maulsby C, Kim JJ, Charles V, Riordan M, et al. Cost-Utility Analysis of Three U.S. HIV Linkage and Re-engagement in Care Programs from Positive Charge. AIDS and behavior. 2016;20(5):973-6.
40.    Strand KB, Chisholm D, Fekadu A, Johansson KA. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health policy and planning. 2016;31(4):504-13.
41.    Zur RM, Zaric GS. A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada. Addiction (Abingdon, England). 2016;111(5):817-31.
42.    Frederix I, Hansen D, Coninx K, Vandervoort P, Vandijck D, Hens N, et al. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis. European journal of preventive cardiology. 2016;23(7):674-82.
43.    Garcia-Ruiz AJ, Quintano Jimenez JA, Garcia-Agua Soler N, Ginel Mendoza L, Hidalgo Requena A, Del Moral F. [Quality of life of patients with asthma on beclomethasone/formoterol. Cost-utility analysis]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):225-34.
44.    De Lossada A, Oteo-Alvaro A, Gimenez S, Oyaguez I, Rejas J. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective]. Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016;42(4):235-43.
45.    Pinol C. Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain. Neurologia (Barcelona, Spain). 2016;31(4):247-54.
46.    Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Clinical spine surgery. 2016.